Dexamethasone protects against membrane formation

Article

Dexamethasone protects against anterior membrane formation and doesn’t increase glaucoma risk.

Dexamethasone protects against anterior membrane formation and doesn’t increase glaucoma risk.

The retrospective case series, led by Dr Asimina Mataftsi, Clinical and Academic Department of Ophthalmology, London, UK, was comprised of 24 eyes of 18 infants who underwent cataract surgery with IOLs between January 1, 2007 and December 31, 2008.

Mean follow-up was 38 months and the median age at surgery was three months. Transient postoperative antihypertensive medication was used in four eyes, but there was no development of glaucoma during the follow-up period.

Of the eyes studied, 15 underwent a second procedure to clear the visual axis caused by posterior visual axis opacification. No eyes developed anterior membranes and Intracameral preservative-free dexamethasone doesn't seem to cause increased glaucoma risk.

To read the abstract please visit the Journal of Cataract and Refractive Surgery.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.